RECCE® 327 Topical Gel shows strong preclinical results Posted on August 19, 2025August 19, 2025 by recce_com RECCE® 327 Topical Gel shows strong preclinical results
Recce secures $30m debt facility to support Phase III trials Posted on June 18, 2025 by recce_com Recce secures $30m debt facility to support Phase III trials
Break it Down: Recce partners with the US Army Posted on April 28, 2025 by recce_com Break it Down: Recce partners with the US Army
Recce to expand Phase II trial for diabetic foot infections Posted on April 22, 2025 by recce_com Recce to expand Phase II trial for diabetic foot infections
Recce raising up to $15.8m for Phase III trials Posted on April 10, 2025 by recce_com Recce raising up to $15.8m for Phase III trials
Biocurious: For Recce, our near neighbour was the obvious place to launch a diabetes-related trial Posted on April 3, 2025 by recce_com Biocurious: For Recce, our near neighbour was the obvious place to launch a diabetes-related trial
Synthetic Gel Shows Utility Across ABSSSI, Company Sees Other Indications Posted on March 6, 2025 by recce_com Synthetic Gel Shows Utility Across ABSSSI, Company Sees Other Indications
Australian biotech points to potential superbug use as gel treats skin infections in phase 2 trial Posted on February 20, 2025April 3, 2025 by recce_com Australian biotech points to potential superbug use as gel treats skin infections in phase 2 trial
Recce soars on phase II skin infection trial results Posted on February 17, 2025 by recce_com Recce soars on phase II skin infection trial results
Recce Pharmaceuticals doses all patients in phase II skin infection trial Posted on January 29, 2025 by recce_com Recce Pharmaceuticals doses all patients in phase II skin infection trial
